Understand Business Like AI

Training Example: REXULTI (Otsuka America Pharmaceutical, Inc.) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

REXULTI (Otsuka America Pharmaceutical, Inc.)

(https://rexulti.com) 📸 Data Snapshot: June 19, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE REXULTI® (brexpiprazole) | Patient Information Website (https://rexulti.com)
Title

REXULTI® (brexpiprazole) | Patient Information Website

Meta

Learn about REXULTI® (brexpiprazole), its uses and how it may help. See Important Safety Info & Full Prescribing Info, including Boxed WARNING.

H1 Could REXULTI help?
H2 Choose a Condition
H3 IMPORTANT SAFETY INFORMATION AND INDICATIONS for REXULTI® (brexpiprazole)
H4 IMPORTANT SAFETY INFORMATION:
H4 INDICATIONS: 
H4 INDICATIONS: 
H4 IMPORTANT SAFETY INFORMATION:
H4 INDICATIONS: 
H5 You Are Now Leaving This Site
NAV_HEADER_REPEATED REXULTI® (brexpiprazole) | Savings & Cost Information (https://rexulti.com/savings-cost/)
Title

REXULTI® (brexpiprazole) | Savings & Cost Information

Meta

Discover the REXULTI Savings Card and download today! Terms and conditions apply. See Important Safety Info & Full Prescribing Info, including Boxed WARNING.

H1 REXULTI® (brexpiprazole) Savings & Cost
H2 Have commercial insurance? Pay as little as $0 to start.
H2 Have Medicare?
H2 Have Medicaid?
H2 Have insurance through Veterans Affairs benefits or TRICARE?
H2 Don’t have insurance coverage right now, or your plan doesn’t cover REXULTI?
H3 Want to know what your prescription may cost? Let’s start with your insurance.
H3 IMPORTANT SAFETY INFORMATION AND INDICATIONS for REXULTI® (brexpiprazole)
H4 REXULTI
H4 Generic antidepressant
H4 IMPORTANT SAFETY INFORMATION:
H4 INDICATIONS: 
H4 INDICATIONS: 
H4 IMPORTANT SAFETY INFORMATION:
H4 INDICATIONS: 
H5 Up to $8,180 applied to your annual deductible with up to 13 uses per calendar-year. Benefit renews annually.§
H5 More about Medicare Part D
H5 You Are Now Leaving This Site
NAV_HEADER_HEADING_REPEATED_BODY REXULTI® (brexpiprazole) | Add On Depression Medication (https://rexulti.com/mdd/)
Title

REXULTI® (brexpiprazole) | Add On Depression Medication

Meta

Discover REXULTI, an add-on treatment for adults with major depressive disorder. See Important Safety Info & Full Prescribing Info, including Boxed WARNING.

H1 Could a BOOST help you build on your progress with depression? Ask your doctor about adding REXULTI.
H2 MDD Main
H2 Feeling stuck? It may be Partial Response.
H2 REXULTI works with your antidepressant.
H2 How to save on REXULTI.
H2 Ready to ask your doctor about REXULTI?
H2 Footer links
H2 Footer logos
H3 INDICATION and IMPORTANT SAFETY INFORMATION for REXULTI® (brexpiprazole)
H3 INDICATIONS and IMPORTANT SAFETY INFORMATION for REXULTI® (brexpiprazole)
H4 INDICATIONS: 
H4 INDICATION: 
H4 IMPORTANT SAFETY INFORMATION:
H4 IMPORTANT SAFETY INFORMATION:
H4 INDICATION: 
H4 INDICATIONS: 
NAV_HEADER_HEADING_REPEATED_BODY REXULTI® (brexpiprazole) | agitation that may happen with dementia due to Alzheimer’s disease (https://rexulti.com/aad/)
Title

REXULTI® (brexpiprazole) | agitation that may happen with dementia due to Alzheimer’s disease

Meta

Discover the only FDA-Approved treatment for agitation that may happen with dementia due to Alzheimer’s disease. See Important Safety Info & Full Prescribing Info, including Boxed WARNING.

H1 Learn about agitation that may happen with dementia due to Alzheimer's disease
H2 Join REXULTI Connect
H2 A caregiver’s story
H2 Receive caregiver tips and educational materials from REXULTI.
H3 IMPORTANT SAFETY INFORMATION and INDICATION for REXULTI® (brexpiprazole)
H4 IMPORTANT SAFETY INFORMATION:
H4 INDICATION: 
H4 IMPORTANT SAFETY INFORMATION:
H4 INDICATION: 
H5 You Are Now Leaving This Site
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://rexulti.com) REXULTI® (brexpiprazole) | Patient Information Website 
Depression
Actor portrayals

Agitation that may happen with dementia due to Alzheimer’s disease
Actor portrayals

Depression
Actor portrayal

Agitation that may happen with dementia due to Alzheimer’s disease
Actor portrayals

Depression
Actor portrayals

Agitation that may happen with dementia due to Alzheimer’s disease
Actor portrayals

Depression
Actor portrayal

Agitation that may happen with dementia due to Alzheimer’s disease
Actor portrayals

[H1] Could REXULTI help?

[H2] Choose a Condition

Depression
Agitation that may happen with dementia due to Alzheimer’s disease

ISI Block Title

[H3] IMPORTANT SAFETY INFORMATION AND INDICATIONS for REXULTI® (brexpiprazole)

[H4] IMPORTANT SAFETY INFORMATION:

Increased risk of death in elderly people with dementia-related psychosis. Medicines like REXULTI can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). REXULTI is not approved for the treatment of people with dementia-related psychosis without agitation that may happen with dementia due to Alzheimer’s disease.
Increased risk of suicidal thoughts and actions. REXULTI and antidepressant medicines may increase suicidal thoughts and actions in pediatric patients and young adult patients, especially within the first few months of treatment or when the dose is changed. Depression and other mental illnesses are the most important causes of suicidal thoughts and actions. All patients on antidepressants and their families or caregivers should closely watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. Report any change in these symptoms immediately to the doctor.

Do not take REXULTI if you are allergic to brexpiprazole or any of the ingredients in REXULTI.

REXULTI may cause serious side effects, including:

Cerebrovascular problems, including stroke, in elderly people with dementia-related psychosis that can lead to death.
Neuroleptic malignant syndrome (NMS) is a serious condition that can lead to death. Call your healthcare provider or go to the nearest hospital emergency room right away if you have some or all of the following signs and symptoms of NMS: high fever; changes in your pulse, blood pressure, heart rate, and breathing; stiff muscles; confusion; increased sweating
Uncontrolled body movements (tardive dyskinesia). REXULTI may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking REXULTI. Tardive dyskinesia may also start after you stop taking REXULTI.
Problems with your metabolism such as:

high blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who take REXULTI. Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before you start, or soon after you start REXULTI and then regularly during long term treatment with REXULTI.
Call your healthcare provider if you have any of these symptoms of high blood sugar during treatment with REXULTI:

feel very thirsty
feel very hungry
feel sick to your stomach

need to urinate more than usual
feel weak or tired
feel confused, or your breath
smells fruity

increased fat levels (cholesterol and triglycerides) in your blood.
Your healthcare provider should check the fat levels in your blood before you start, or soon after you start REXULTI, and then periodically during treatment with REXULTI.
weight gain. You and your healthcare provider should check your weight before you start and often during treatment with REXULTI.

Unusual and uncontrollable (compulsive) urges. Some people taking REXULTI have had strong unusual urges, to gamble and gambling that cannot be controlled (compulsive gambling). Other compulsive urges include sexual urges, shopping, and eating or binge eating. If you or your family members notice that you are having new or unusual strong urges or behaviors, talk to your healthcare provider.
Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with REXULTI.
Decreased blood pressure (orthostatic hypotension) and fainting. You may feel dizzy, lightheaded or pass out (faint) when you rise too quickly from a sitting or lying position.
Falls. REXULTI may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries.
Seizures (convulsions).
Problems controlling your body temperature so that you feel too warm. Do not become too hot or dehydrated during treatment with REXULTI. Do not exercise too much. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much clothing or heavy clothing. Drink plenty of water.
Difficulty swallowing that can cause food or liquid to get into your lungs.
Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities. Do not drive a car, operate machinery, or do other dangerous activities until you know how REXULTI affects you. REXULTI may make you feel drowsy.

Before taking REXULTI, tell your healthcare provider about all of your medical conditions, including if you:

have or have had heart problems or a stroke
have or have had low or high blood pressure
have or have had diabetes or high blood sugar or a family history of diabetes or high blood sugar.
have or have had high levels of total cholesterol, LDL cholesterol, or triglycerides, or low levels of HDL cholesterol
have or have had seizures (convulsions)
have or have had kidney or liver problems
have or have had a low white blood cell count
are pregnant or plan to become pregnant. REXULTI may harm your unborn baby. Taking REXULTI during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms after birth. Talk to your healthcare provider about the risk to your unborn baby if you take REXULTI during pregnancy.

Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with REXULTI.
There is a pregnancy exposure registry for women who are exposed to REXULTI during pregnancy. If you become pregnant during treatment with REXULTI, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychiatric Medications.
You can register by calling 1-866-961-2388 or visit
http://womensmentalhealth.org/‌clinical-and-research-programs/‌pregnancyregistry/.

are breastfeeding or plan to breastfeed. It is not known if REXULTI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with REXULTI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. REXULTI and other medicines may affect each other causing possible serious side effects. REXULTI may affect the way other medicines work, and other medicines may affect how REXULTI works. Your healthcare provider can tell you if it is safe to take REXULTI with your other medicines. Do not start or stop any medicines during treatment with REXULTI without first talking to your healthcare provider.

The most common side effects of REXULTI include weight gain, sleepiness, dizziness, common cold symptoms, and restlessness or feeling like you need to move (akathisia).

These are not all the possible side effects of REXULTI. For more information, ask your healthcare provider or pharmacist.

You are encouraged to report side effects of REXULTI (brexpiprazole). Please contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

[H4] INDICATIONS:

REXULTI is a prescription medicine used:

along with antidepressant medicines to treat major depressive disorder (MDD) in adults
to treat agitation that may happen with dementia due to Alzheimer’s disease

REXULTI should not be used as an “as needed” treatment for agitation that may happen with dementia due to Alzheimer’s disease.

It is not known if REXULTI is safe and effective in children with MDD.

Please read FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE.

[H4] INDICATIONS:

REXULTI is a prescription medicine used:

along with antidepressant medicines to treat major depressive disorder (MDD) in adults
to treat agitation that may happen with dementia due to Alzheimer’s disease

REXULTI should not be used as an “as needed” treatment for agitation that may happen with dementia due to Alzheimer’s disease.

It is not known if REXULTI is safe and effective in children with MDD.
9127 chars
SUB-PAGE (https://rexulti.com/savings-cost/) REXULTI® (brexpiprazole) | Savings & Cost Information 
Image mobile

[H1] REXULTI® (brexpiprazole) Savings & Cost

[H3] Want to know what your prescription may cost? Let’s start with your insurance.

The list price, also known as the Wholesale Acquisition Cost (WAC), of REXULTI is $1,555.86 per month,* but most patients pay less with their prescription drug plan.

[H2]

Commercial Insurance

medicare

Medicaid

VA OR Tricare

Uninsured

Commercial Insurance

[H2]

Have commercial insurance? Pay as little as $0 to start.

If you’ve been prescribed REXULTI and have commercial insurance, you may be eligible for the REXULTI Savings Card.† That means you could pay as little as:
$0  for REXULTI refills.
$0  for 90-day prescriptions.
Plus, pay as little as $0 per month for a generic antidepressant (if prescribed).
Click here to view Savings Terms & Conditions.
Ready to begin registration? Click the button below.
Register for Savings Card
Or we can text you a Savings Card – just send “SAVE” to 96747.¶

While your cost for REXULTI will depend on your specific plan, the average cost is $12.51 per month.‡
Because each plan has different preferred drugs, out-of-pocket costs, and deductible requirements, talk to your insurance provider to find out your actual cost.

The REXULTI Savings Card can provide benefits for both REXULTI and a generic antidepressant.†

[H4] REXULTI
REXULTI refills as little as...............  $0
90-day prescriptions as little as.....  $0
[H4] Generic antidepressant
Your generic antidepressant for as little as............................... $0
Your generic antidepressant for as little as.... $0
(for up to 12 uses)
Covered generic antidepressants
[H5] Up to $8,180 applied to your annual deductible with up to 13 uses per calendar-year.
Benefit renews annually.§

Additional assistance

Have a prescription but not insured or need help paying for your REXULTI? Learn about additional assistance.#
Find Out More

Have more questions?

Read our FAQs or call us at 1-844-415-0674.
A representative will be available to help you 24/7.
SAVING CARD FAQS

Already prescribed REXULTI?

Otsuka has established the Integrated Pharmacy Network (IPN), which includes a group of participating pharmacies familiar with navigating various aspects of the healthcare system. The IPN finder tool can help you locate pharmacies that may provide support with general questions related to insurance, treatment logistics, or other practical considerations.
Find an IPN pharmacy near you

Use current location

Get reimbursed for your prescription by mail.

Using mail order or already paid for your prescription and need reimbursement? Download and mail the Reimbursement Form.
DOWNLOAD FORM

*This is the price REXULTI is sold to wholesalers/pharmacies as of February 2026.
†For eligible commercially insured patients who are prescribed REXULTI. Benefits apply to copays, co-insurance, and pharmacy deductibles. Maximum annual benefit applies based on current list price. Click for full terms and conditions below. For up to 13 uses. Resets annually.
‡IQVIA LAAD data, December 2024-November 2025.
§Terms and conditions apply.
¶Message and data rates apply. Message frequency varies. Text HELP for help and STOP to opt-out. Otsuka may use pharmacy information to provide refill reminders with your consent. Click here for privacy policy.
#There is no guarantee that you will be approved for prescription assistance through the Otsuka Patient Assistance Foundation (OPAF). Additional information regarding insurance coverage and income may be needed before you receive approval.

medicare

[H2]

Have Medicare?

With Medicare, out-of-pocket costs for REXULTI prescriptions average about $21.51 per month.† Of course, out-of-pocket costs vary throughout the year, depending on which phase of Part D you’re in and if you're enrolled in a Medicare Prescription Payment Plan (MPPP).
Your cost could be less if you’re eligible for the Social Security Administration’s Extra Help program.
Visit https://www.ssa.gov/‌benefits/‌medicare/‌prescriptionhelp/ for more information and to see if you qualify.

[H5] More about Medicare Part D

Find out what's changed
Download a guide to learn what's changing for
Medicare Part D in 2026.
Download guide

Additional assistance

Have a prescription but not insured or need help paying for your REXULTI? Learn about additional assistance.§
Find Out More

Have more questions?

Call us at 1-833-468-7852.
A representative will be available to help you 24/7.

State Health Insurance Assistance Programs (SHIPs)

SHIPs provide local, in-depth, and unbiased insurance counseling and assistance to Medicare-eligible individuals, their families, and caregivers.
LEARN MORE

Already prescribed REXULTI?

Otsuka has established the Integrated Pharmacy Network (IPN), which includes a group of participating pharmacies familiar with navigating various aspects of the healthcare system. The IPN finder tool can help you locate pharmacies that may provide support with general questions related to insurance, treatment logistics, or other practical considerations.
Find an IPN pharmacy near you

Use current location

*This is the price REXULTI is sold to wholesalers/pharmacies as of February 2026.
†IQVIA LAAD data, December 2024-November 2025.
§There is no guarantee that you will be approved for prescription assistance through the Otsuka Patient Assistance Foundation (OPAF). Additional information regarding insurance coverage and income may be needed before you receive approval.

Medicaid

[H2]

Have Medicaid?

With Medicaid, the cost of REXULTI averages about $14.18 per month.† You may pay more or less depending on your state’s formulary.
To find out if you qualify for Medicaid, or to learn more about copayments in your state, visit https://www.medicaid.gov/‌state-overviews/‌index.html.

Additional assistance

Have a prescription but not insured or need help paying for your REXULTI? Learn about additional assistance.§
Find Out More

Have more questions?

Call us at 1-833-468-7852.
A representative will be available to help you 24/7.

State Health Insurance Assistance Programs (SHIPs)

SHIPs provide local, in-depth, and unbiased insurance counseling and assistance to Medicare-eligible individuals, their families, and caregivers.
LEARN MORE

Already prescribed REXULTI?

Otsuka has established the Integrated Pharmacy Network (IPN), which includes a group of participating pharmacies familiar with navigating various aspects of the healthcare system. The IPN finder tool can help you locate pharmacies that may provide support with general questions related to insurance, treatment logistics, or other practical considerations.
Find an IPN pharmacy near you

Use current location

*This is the price REXULTI is sold to wholesalers/pharmacies as of February 2026.
†IQVIA LAAD data, December 2024-November 2025.
§There is no guarantee that you will be approved for prescription assistance through the Otsuka Patient Assistance Foundation (OPAF). Additional information regarding insurance coverage and income may be needed before you receive approval.

VA OR Tricare

[H2]

Have insurance through Veterans Affairs benefits or TRICARE?

With VA benefits or TRICARE, the cost of a REXULTI prescription averages $71.89 per month,† but your copay may vary depending on certain criteria and qualifications.
You may also be eligible to pay no copays.
To find out if you qualify for VA benefits or TRICARE, or for more information about copayments, you can visit:
VA health benefits
TRICARE

Additional assistance

Have a prescription but not insured or need help paying for your REXULTI? Learn about additional assistance.§
Find Out More

Have more questions?

Call us at 1-833-468-7852.
A representative will be available to help you 24/7.

State Health Insurance Assistance Programs (SHIPs)

SHIPs provide local, in-depth, and unbiased insurance counseling and assistance to Medicare-eligible individuals, their families, and caregivers.
LEARN MORE

Already prescribed REXULTI?

Otsuka has established the Integrated Pharmacy Network (IPN), which includes a group of participating pharmacies familiar with navigating various aspects of the healthcare system. The IPN finder tool can help you locate pharmacies that may provide support with general questions related to insurance, treatment logistics, or other practical considerations.
Find an IPN pharmacy near you

Use current location

*This is the price REXULTI is sold to wholesalers/pharmacies as of February 2026.
†IQVIA LAAD data, December 2024-November 2025.
§There is no guarantee that you will be approved for prescription assistance through the Otsuka Patient Assistance Foundation (OPAF). Additional information regarding insurance coverage and income may be needed before you receive approval.

Uninsured

[H2]

Don’t have insurance coverage right now, or your plan doesn’t cover REXULTI?

If you don’t have insurance or your plan doesn’t cover REXULTI, you can expect to pay the list price noted above, plus any applicable pharmacy charges.

Additional assistance

Have a prescription but not insured or need help paying for your REXULTI? Learn about additional assistance.†
Find Out More

Have more questions?

Call us at 1-833-468-7852.
A representative will be available to help you 24/7.

State Health Insurance Assistance Programs (SHIPs)

SHIPs provide local, in-depth, and unbiased insurance counseling and assistance to Medicare-eligible individuals, their families, and caregivers.
LEARN MORE

Already prescribed REXULTI?

Otsuka has established the Integrated Pharmacy Network (IPN), which includes a group of participating pharmacies familiar with navigating various aspects of the healthcare system. The IPN finder tool can help you locate pharmacies that may provide support with general questions related to insurance, treatment logistics, or other practical considerations.
Find an IPN pharmacy near you

Use current location

*This is the price REXULTI is sold to wholesalers/pharmacies as of February 2026.
†There is no guarantee that you will be approved for prescription assistance through the Otsuka Patient Assistance Foundation (OPAF). Additional information regarding insurance coverage and income may be needed before you receive approval.

ISI Block Title

[H3] IMPORTANT SAFETY INFORMATION AND INDICATIONS for REXULTI® (brexpiprazole)

[H4] IMPORTANT SAFETY INFORMATION:

Increased risk of death in elderly people with dementia-related psychosis. Medicines like REXULTI can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). REXULTI is not approved for the treatment of people with dementia-related psychosis without agitation that may happen with dementia due to Alzheimer’s disease.
Increased risk of suicidal thoughts and actions. REXULTI and antidepressant medicines may increase suicidal thoughts and actions in pediatric patients and young adult patients, especially within the first few months of treatment or when the dose is changed. Depression and other mental illnesses are the most important causes of suicidal thoughts and actions. All patients on antidepressants and their families or caregivers should closely watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. Report any change in these symptoms immediately to the doctor.

Do not take REXULTI if you are allergic to brexpiprazole or any of the ingredients in REXULTI.

REXULTI may cause serious side effects, including:

Cerebrovascular problems, including stroke, in elderly people with dementia-related psychosis that can lead to death.
Neuroleptic malignant syndrome (NMS) is a serious condition that can lead to death. Call your healthcare provider or go to the nearest hospital emergency room right away if you have some or all of the following signs and symptoms of NMS: high fever; changes in your pulse, blood pressure, heart rate, and breathing; stiff muscles; confusion; increased sweating
Uncontrolled body movements (tardive dyskinesia). REXULTI may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking REXULTI. Tardive dyskinesia may also start after you stop taking REXULTI.
Problems with your metabolism such as:

high blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who take REXULTI. Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before you start, or soon after you start REXULTI and then regularly during long term treatment with REXULTI.
Call your healthcare provider if you have any of these symptoms of high blood sugar during treatment with REXULTI:

feel very thirsty
feel very hungry
feel sick to your stomach

need to urinate more than usual
feel weak or tired
feel confused, or your breath
smells fruity

increased fat levels (cholesterol and triglycerides) in your blood.
Your healthcare provider should check the fat levels in your blood before you start, or soon after you start REXULTI, and then periodically during treatment with REXULTI.
weight gain. You and your healthcare provider should check your weight before you start and often during treatment with REXULTI.

Unusual and uncontrollable (compulsive) urges. Some people taking REXULTI have had strong unusual urges, to gamble and gambling that ca
15000 chars
SUB-PAGE · THIN (https://rexulti.com/mdd/) REXULTI® (brexpiprazole) | Add On Depression Medication 
[IMG: Neutal face icon]

[H2] Feeling stuck? It may be Partial Response.
If you’re taking an antidepressant and still feeling depressed, there might be more you and your doctor can do.

LEARN
MORE

[IMG: Plus sign icon]

[H2] REXULTI works with your antidepressant.
Add REXULTI and help build on your progress without starting over.

HOW REXULTI CAN HELP

[IMG: Savings card icon]

[H2] How to save on REXULTI.
1 savings card, 2 separate benefits.

GET THE SAVINGS CARD

[IMG: Doctor icon]

[H2] Ready to ask your doctor about REXULTI?
Our Symptom Questionnaire can help get the conversation started.

TAKE THE QUESTIONNAIRE
703 chars
SUB-PAGE (https://rexulti.com/aad/) REXULTI® (brexpiprazole) | agitation that may happen with dementia due to Alzheimer’s disease 
[H1] Learn about agitation that may happen with dementia due to Alzheimer's disease

About this condition
Why REXULTI?
Symptom Questionnaire

[H2]
Join REXULTI Connect

Get helpful information delivered straight to your inbox. Expect tips and resources designed to help you navigate your loved one’s next steps—from symptom check-ins to information on financial assistance and more.

Sign up now

[IMG: Join REXULTI Connect]
[IMG: Join REXULTI Connect]
Actor portrayals

[H2]
A caregiver’s story

Hear Natasha’s firsthand experience caring for her loved one with agitation that may happen with dementia due to Alzheimer's disease.

Watch now

[IMG: Thumbnail for REXULTI caregiver story video about caregiver and her loved one with agitation that may happen with dementia due to Alzheimer]
[IMG: Thumbnail for REXULTI caregiver story video about caregiver and her loved one with agitation that may happen with dementia due to Alzheimer]
Natasha, caregiver

Natasha is a caregiver ambassador and has been compensated by Otsuka America Pharmaceutical, Inc. and Lundbeck for her time. Patient images reflect health status at time of recording.

ISI Block Title

[H3] IMPORTANT SAFETY INFORMATION and INDICATION for REXULTI® (brexpiprazole)

[H4] IMPORTANT SAFETY INFORMATION:

Increased risk of death in elderly people with dementia-related psychosis. Medicines like REXULTI can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). REXULTI is not approved for the treatment of people with dementia-related psychosis without agitation that may happen with dementia due to Alzheimer’s disease.

Do not take REXULTI if you are allergic to brexpiprazole or any of the ingredients in REXULTI.

REXULTI may cause serious side effects, including:

Cerebrovascular problems, including stroke, in elderly people with dementia-related psychosis that can lead to death.
Neuroleptic malignant syndrome (NMS) is a serious condition that can lead to death. Call your healthcare provider or go to the nearest hospital emergency room right away if you have some or all of the following signs and symptoms of NMS: high fever; changes in your pulse, blood pressure, heart rate, and breathing; stiff muscles; confusion; increased sweating.
Uncontrolled body movements (tardive dyskinesia). REXULTI may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking REXULTI. Tardive dyskinesia may also start after you stop taking REXULTI.
Problems with your metabolism such as:

high blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who take REXULTI. Extremely high blood sugar can lead to coma or death. Your healthcare provider should check your blood sugar before you start, or soon after you start REXULTI and then regularly during long term treatment with REXULTI.
Call your healthcare provider if you have any of these symptoms of high blood sugar during treatment with REXULTI:

feel very thirsty
feel very hungry
feel sick to your stomach

need to urinate more than usual
feel weak or tired
feel confused, or your breath smells fruity

increased fat levels (cholesterol and triglycerides) in your blood. Your healthcare provider should check the fat levels in your blood before you start, or soon after you start REXULTI, and then periodically during treatment with REXULTI.
weight gain. You and your healthcare provider should check your weight before you start and often during treatment with REXULTI.

Unusual and uncontrollable (compulsive) urges. Some people taking REXULTI have had strong unusual urges, to gamble and gambling that cannot be controlled (compulsive gambling). Other compulsive urges include sexual urges, shopping, and eating or binge eating. If you or your family members notice that you are having new or unusual strong urges or behaviors, talk to your healthcare provider.
Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with REXULTI.
Decreased blood pressure (orthostatic hypotension) and fainting. You may feel dizzy, lightheaded or pass out (faint) when you rise too quickly from a sitting or lying position.
Falls. REXULTI may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries.
Seizures (convulsions).
Problems controlling your body temperature so that you feel too warm. Do not become too hot or dehydrated during treatment with REXULTI. Do not exercise too much. In hot weather, stay inside in a cool place if possible. Stay out of the sun. Do not wear too much clothing or heavy clothing. Drink plenty of water.
Difficulty swallowing that can cause food or liquid to get into your lungs.
Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities. Do not drive a car, operate machinery, or do other dangerous activities until you know how REXULTI affects you. REXULTI may make you feel drowsy.

Before taking REXULTI, tell your healthcare provider about all of your medical conditions, including if you:

have or have had heart problems or a stroke
have or have had low or high blood pressure
have or have had diabetes or high blood sugar or a family history of diabetes or high blood sugar.
have or have had high levels of total cholesterol, LDL cholesterol, or triglycerides, or low levels of HDL cholesterol
have or have had seizures (convulsions)
have or have had kidney or liver problems
have or have had a low white blood cell count
are pregnant or plan to become pregnant. REXULTI may harm your unborn baby. Taking REXULTI during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms after birth. Talk to your healthcare provider about the risk to your unborn baby if you take REXULTI during pregnancy.

Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with REXULTI.
There is a pregnancy exposure registry for women who are exposed to REXULTI during pregnancy. If you become pregnant during treatment with REXULTI, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychiatric Medications. You can register by calling 1-866-961-2388 or visit
http://‌womensmentalhealth.org/‌clinical-and-research-programs/‌pregnancyregistry/.

are breastfeeding or plan to breastfeed. It is not known if REXULTI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with REXULTI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. REXULTI and other medicines may affect each other causing possible serious side effects. REXULTI may affect the way other medicines work, and other medicines may affect how REXULTI works. Your healthcare provider can tell you if it is safe to take REXULTI with your other medicines. Do not start or stop any medicines during treatment with REXULTI without first talking to your healthcare provider.

The most common side effects of REXULTI include weight gain, sleepiness, dizziness, common cold symptoms, and restlessness or feeling like you need to move (akathisia).

These are not all the possible side effects of REXULTI. For more information, ask your healthcare provider or pharmacist.

You are encouraged to report side effects of REXULTI (brexpiprazole). Please contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE.

[H4] INDICATION:

REXULTI is a prescription medicine used to treat agitation that may happen with dementia due to Alzheimer’s disease.

REXULTI should not be used as an “as needed” treatment for agitation that may happen with dementia due to Alzheimer’s disease.
8469 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
11Review mentions (all pages)
0External proof links (all pages)
PageReviewsProof links
/ (home) 2 0
/savings-cost/ 5 0
/mdd/ 2 0
/aad/ 2 0
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema 
{
    "@context": "https://schema.org",
    "@type": "WebSite",
    "name": "REXULTI Consumer Website",
    "url": "https://www.rexulti.com/",
    "hasPart": {
        "@type": "MedicalWebPage",
        "url": "https://www.rexulti.com/",
        "name": "REXULTI® (brexpiprazole) | Patient Information Website",
        "description": "Learn about REXULTI® (brexpiprazole), its uses and how it may help. See Important Safety Info & Full Prescribing Info, including Boxed WARNING.",
        "headline": "Could REXULTI help?",
        "relatedLink": "https://www.rexulti.com/mdd https://www.rexulti.com/aad https://www.rexulti.com/us/sz https://www.rexulti.com/important-safety-information https://www.rexulti.com/savings-cost",
        "primaryImageOfPage": "https://www.rexulti.com/sites/g/files/qhldwo10756/files/GettyImages-650146050%204.jpg",
        "audience": {
            "@type": "Patient",
            "additionalName": "Consumer"
        },
        "hasPart": [
            {
                "@type": "MedicalWebPage",
                "url": "https://www.rexulti.com/mdd",
                "disambiguatingDescription": [
                    "REXULTI for MDD",
                    "REXULTI for Major Depression",
                    "REXULTI for depression"
                ],
                "isPartOf": "https://www.rexulti.com/",
                "mainEntity": {
                    "@type": "MedicalCondition",
                    "name": "Major Depressive Disorder",
                    "alternateName": [
                        "MDD",
                        "depression",
                        "Major Depressive Disorder"
                    ],
                    "sameAs": "https://en.wikipedia.org/wiki/Major_depressive_disorder",
                    "possibleTreatment": {
                        "@type": "MedicalTherapy",
                        "drug": {
                            "@type": "Drug",
                            "name": "REXULTI® (brexpiprazole)",
                            "proprietaryName": "Rexulti",
                            "mainEntityOfPage": "https://www.rexulti.com/"
                        }
                    }
                }
            },
            {
                "@type": "MedicalWebPage",
                "url": "https://www.rexulti.com/aad",
                "disambiguatingDescription": [
                    "REXULTI for AAD",
                    "REXULTI for Alzheimer's",
                    "REXULTI for Dementia",
                    "REXULTI for agitation"
                ],
                "isPartOf": "https://www.rexulti.com/",
                "mainEntity": {
                    "@type": "MedicalCondition",
                    "name": "Agitation that may happen with dementia due to Alzheimer's disease",
                    "alternateName": [
                        "agitation in alzheimer's dementia",
                        "aad",
                        "agitation in dementia"
                    ],
                    "sameAs": "https://en.wikipedia.org/wiki/Agitation_(dementia)",
                    "possibleTreatment": {
                        "@type": "MedicalTherapy",
                        "drug": {
                            "@type": "Drug",
                            "name": "REXULTI® (brexpiprazole)",
                            "proprietaryName": "Rexulti",
                            "mainEntityOfPage": "https://www.rexulti.com/"
                        }
                    }
                }
            },
            {
                "@type": "MedicalWebPage",
                "url": "https://www.rexulti.com/us/sz",
                "disambiguatingDescription": "REXULTI for Schizophrenia",
                "isPartOf": "https://www.rexulti.com/",
                "mainEntity": {
                    "@type": "MedicalCondition",
                    "name": "Schizophrenia",
                    "sameAs": "https://en.wikipedia.org/wiki/Schizophrenia",
                    "possibleTreatment": {
                        "@type": "MedicalTherapy",
                        "drug": {
                            "@type": "Drug",
                            "name": "REXULTI® (brexpiprazole)",
                            "proprietaryName": "Rexulti",
                            "mainEntityOfPage": "https://www.rexulti.com/"
                        }
                    }
                }
            }
        ],
        "about": {
            "@type": "Drug",
            "name": "REXULTI® (brexpiprazole)",
            "logo": "https://www.rexulti.com/sites/g/files/qhldwo10756/files/logo3x.png",
            "manufacturer": "Otsuka America Pharmaceutical, Inc.",
            "warning": "https://www.rexulti.com/important-safety-information",
            "prescribingInfo": "https://otsuka-us.com/sites/g/files/qhldwo10991/files/media/static/Rexulti-PI.pdf",
            "proprietaryName": "Rexulti",
            "activeIngredient": "brexpiprazole",
            "dosageForm": "Tablet",
            "drugClass": {
                "@type": "DrugClass",
                "name": "Atypical Antipsychotics"
            },
            "administrationRoute": "Oral",
            "prescriptionStatus": "https://schema.org/PrescriptionOnly",
            "sameAs": "https://en.wikipedia.org/wiki/Brexpiprazole"
        },
        "mentions": {
            "@type": "TreatmentIndication",
            "name": "INDICATIONS",
            "description": "REXULTI is indicated for: Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults, Treatment of schizophrenia in adults and pediatric patients ages 13 years and older, Treatment of agitation associated with dementia due to Alzheimer’s disease"
        },
        "specialty": "https://schema.org/Psychiatric",
        "publisher": {
            "@type": "Organization",
            "name": "Otsuka America Pharmaceutical, Inc.",
            "url": "https://otsuka-us.com/",
            "brand": {
                "@type": "Brand",
                "name": "REXULTI®",
                "logo": "https://www.rexulti.com/sites/g/files/qhldwo10756/files/logo3x.png"
            }
        }
    }
}
/savings-cost/ 
{
    "@context": "https://schema.org",
    "@type": "WebPage",
    "url": "https://www.rexulti.com/savings-cost",
    "name": "REXULTI® (brexpiprazole) | Savings & Cost Information",
    "description": "Discover the REXULTI Savings Card and download today! Terms and conditions apply. See Important Safety Info & Full Prescribing Info, including Boxed WARNING.",
    "headline": "REXULTI® (brexpiprazole) Savings & Cost",
    "relatedLink": "https://www.rexulti.com/ https://www.rexulti.com/mdd https://www.rexulti.com/aad https://www.rexulti.com/us/sz https://www.rexulti.com/important-safety-information",
    "significantLink": "https://www.rexultisavings.com/",
    "audience": {
        "@type": "Patient",
        "additionalName": "Consumer"
    },
    "about": {
        "@type": "Drug",
        "name": "REXULTI® (brexpiprazole)",
        "logo": "https://www.rexulti.com/sites/g/files/qhldwo10756/files/logo3x.png",
        "manufacturer": "Otsuka America Pharmaceutical, Inc.",
        "warning": "https://www.rexulti.com/important-safety-information",
        "prescribingInfo": "https://otsuka-us.com/sites/g/files/qhldwo10991/files/media/static/Rexulti-PI.pdf",
        "proprietaryName": "Rexulti",
        "activeIngredient": "brexpiprazole",
        "dosageForm": "Tablet",
        "drugClass": {
            "@type": "DrugClass",
            "name": "Atypical Antipsychotics"
        },
        "administrationRoute": "Oral",
        "prescriptionStatus": "https://schema.org/PrescriptionOnly",
        "sameAs": "https://en.wikipedia.org/wiki/Brexpiprazole"
    },
    "mentions": {
        "@type": "MedicalIndication",
        "name": "INDICATION",
        "description": "REXULTI is indicated for: Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults, Treatment of schizophrenia in adults and pediatric patients ages 13 years and older, Treatment of agitation associated with dementia due to Alzheimer’s disease"
    },
    "video": {
        "@type": "VideoObject",
        "name": "More about Medicare Part D",
        "alternateName": "Have Medicare?",
        "description": "Learn about Payment Phases",
        "thumbnailUrl": "https://i.vimeocdn.com/video/1767429859-5ef0ad1ada9de6ce5c822201fde407b2ed364a74a51af136667236f01bb35917-d_640",
        "embedUrl": "https://player.vimeo.com/video/893606097",
        "duration": "PT245S",
        "uploadDate": "2023-12-12T01:43:50-05:00"
    },
    "specialty": "https://schema.org/Psychiatric",
    "publisher": {
        "@type": "Organization",
        "name": "Otsuka America Pharmaceutical, Inc.",
        "url": "https://otsuka-us.com/",
        "brand": {
            "@type": "Brand",
            "name": "REXULTI®",
            "logo": "https://www.rexulti.com/sites/g/files/qhldwo10756/files/logo3x.png"
        }
    }
}
/mdd/ 
{
    "@context": "https://schema.org",
    "@graph": [
        {
            "@type": "MedicalWebPage",
            "@id": "https://www.rexulti.com/mdd/#medwebpage",
            "url": "https://www.rexulti.com/mdd",
            "name": "REXULTI® (brexpiprazole) | Add On Depression Medication",
            "description": "Discover REXULTI, an add-on treatment for adults with major depressive disorder. See Important Safety Info & Full Prescribing Info, including Boxed WARNING.",
            "disambiguatingDescription": [
                "REXULTI for MDD",
                "REXULTI for depression",
                "REXULTI add on depression medication",
                "REXULTI for major depressive disorder"
            ],
            "primaryImageOfPage": {
                "@type": "ImageObject",
                "@id": "https://www.rexulti.com/mdd/#primaryimage",
                "url": "https://www.rexulti.com/sites/g/files/qhldwo13186/files/HeroHomeMddImageMobile.png",
                "width": 300,
                "height": 364,
                "caption": "REXULTI for depression user smiling while holding smiley face sign."
            },
            "isPartOf": {
                "@type": "WebSite",
                "@id": "https://www.rexulti.com/#website",
                "url": "https://www.rexulti.com/"
            },
            "about": [
                {
                    "@type": "MedicalCondition",
                    "@id": "https://www.rexulti.com/mdd/depression-partial-response/#medcondition"
                },
                {
                    "@id": "https://www.rexulti.com/#drug"
                }
            ],
            "mentions": {
                "@id": "https://www.rexulti.com/mdd/#indication"
            },
            "relatedLink": [
                "https://www.rexulti.com/mdd/why-rexulti",
                "https://www.rexulti.com/mdd/talk-to-your-doctor",
                "https://www.rexulti.com/mdd/depression-symptom-questionnaire",
                "https://www.rexulti.com/mdd/managing-depression",
                "https://www.rexulti.com/mdd/tools-resources",
                "https://www.rexulti.com/mdd/questions-answers",
                "https://www.rexulti.com/mdd/depression-partial-response",
                "https://www.rexulti.com/mdd/important-safety-information",
                "https://www.rexulti.com/mdd/registration",
                "https://www.rexulti.com/mdd/tv",
                "https://www.rexulti.com/mdd/video-series",
                "https://www.rexulti.com/mdd/video-series/episode-1",
                "https://www.rexulti.com/mdd/video-series/episode-2",
                "https://www.rexulti.com/mdd/video-series/episode-3",
                "https://www.rexulti.com/mdd/video-series/episode-4",
                "https://www.rexulti.com/mdd/video-series/episode-5",
                "https://www.rexulti.com/mdd/video-series/episode-6"
            ],
            "medicalAudience": {
                "@type": "MedicalAudience",
                "name": "Patients",
                "healthCondition": {
                    "@type": "MedicalCondition",
                    "@id": "https://www.rexulti.com/mdd/depression-partial-response/#medcondition"
                }
            },
            "publisher": {
                "@id": "https://otsuka-us.com/#organization"
            }
        },
        {
            "@type": "Drug",
            "@id": "https://www.rexulti.com/#drug",
            "name": "REXULTI® (brexpiprazole)",
            "sameAs": [
                "https://www.wikidata.org/wiki/Q2924764",
                "https://en.wikipedia.org/wiki/Brexpiprazole"
            ],
            "logo": {
                "@type": "ImageObject",
                "@id": "https://www.rexulti.com/#logo"
            },
            "manufacturer": {
                "@id": "https://otsuka-us.com/#organization"
            },
            "brand": {
                "@id": "https://www.rexulti.com/#brand"
            },
            "warning": "https://www.rexulti.com/mdd/important-safety-information",
            "prescribingInfo": "https://otsuka-us.com/media/static/Rexulti-PI.pdf",
            "proprietaryName": "Rexulti",
            "isProprietary": true,
            "activeIngredient": "brexpiprazole",
            "drugClass": {
                "@type": "DrugClass",
                "name": "Atypical Antipsychotics"
            },
            "dosageForm": "Tablet",
            "administrationRoute": "Oral",
            "relevantSpecialty": "https://schema.org/Psychiatric",
            "prescriptionStatus": "https://schema.org/PrescriptionOnly"
        },
        {
            "@type": "ApprovedIndication",
            "@id": "https://www.rexulti.com/mdd/#indication",
            "name": "Major Depressive Disorder",
            "description": "REXULTI is a prescription medicine used along with antidepressant medicines to treat major depressive disorder (MDD) in adults. It is not known if REXULTI is safe and effective in children with MDD.",
            "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850",
            "sameAs": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205422Orig1Orig2s000lbl.pdf",
            "code": {
                "@type": "MedicalCode",
                "codeValue": "F32.9",
                "codingSystem": "ICD-10"
            },
            "recognizingAuthority": {
                "@type": "Organization",
                "name": "U.S. Food and Drug Administration (FDA)",
                "url": "https://www.fda.gov"
            }
        },
        {
            "@type": "Organization",
            "@id": "https://otsuka-us.com/#organization",
            "name": "Otsuka America Pharmaceutical, Inc.",
            "logo": {
                "@type": "ImageObject",
                "@id": "https://otsuka-us.com/#logo",
                "url": "https://www.otsuka-us.com/sites/g/files/qhldwo12546/themes/site/themes/custom/otsuka_corp/logo.svg",
                "width": 75,
                "height": 31,
                "caption": "Ostuka logo"
            },
            "url": "https://otsuka-us.com/",
            "brand": {
                "@id": "https://www.rexulti.com/#brand"
            },
            "sameAs": [
                "https://www.facebook.com/OtsukaUS",
                "https://twitter.com/otsukaus",
                "https://www.instagram.com/otsuka_us/",
                "https://www.threads.net/@otsuka_us",
                "https://www.youtube.com/@otsukaus416"
            ]
        },
        {
            "@type": "Brand",
            "@id": "https://www.rexulti.com/#brand",
            "name": "REXULTI®",
            "url": "https://www.rexulti.com/",
            "logo": {
                "@type": "ImageObject",
                "@id": "https://www.rexulti.com/#logo",
                "url": "https://www.rexulti.com/sites/g/files/qhldwo12851/files/logo%403x.png",
                "width": 600,
                "height": 261,
                "caption": "Rexulti logo"
            },
            "description": "REXULTI is a prescription medicine used: along with antidepressant medicines to treat major depressive disorder (MDD) in adults; to treat agitation that may happen with dementia due to Alzheimer’s disease"
        }
    ]
}
/aad/ 
{
    "@context": "https://schema.org",
    "@graph": [
        {
            "@type": [
                "WebPage",
                "MedicalWebPage"
            ],
            "@id": "https://www.rexulti.com/aad/#medwebpage",
            "url": "https://www.rexulti.com/aad",
            "name": "REXULTI® (brexpiprazole) | agitation that may happen with dementia due to Alzheimer’s disease",
            "description": "Discover the only FDA-Approved treatment for agitation that may happen with dementia due to Alzheimer’s disease. See Important Safety Info & Full Prescribing Info, including Boxed WARNING.",
            "headline": "Learn about agitation that may happen with dementia due to Alzheimer's disease.",
            "disambiguatingDescription": [
                "REXULTI for AAD",
                "REXULTI for Alzheimer's",
                "REXULTI for Dementia",
                "REXULTI for agitation"
            ],
            "breadcrumb": {
                "@id": "https://www.rexulti.com/aad/#breadcrumb"
            },
            "hasPart": {
                "@id": "https://www.rexulti.com/aad/#header-navigation"
            },
            "relatedLink": [
                "https://www.rexulti.com/aad/why-rexulti",
                "https://www.rexulti.com/aad/living-with-agitation-in-alzheimers",
                "https://www.rexulti.com/aad/symptom-questionnaire",
                "https://www.rexulti.com/aad/doctor-discussion-guide",
                "https://www.rexulti.com/aad/resources-and-organizations",
                "https://www.rexulti.com/aad/frequently-asked-questions",
                "https://www.rexulti.com/aad/important-safety-information",
                "https://www.rexulti.com/aad/helpful-videos",
                "https://www.rexulti.com/aad/caregiver-registration",
                "https://www.rexulti.com/aad/disease-impact"
            ],
            "medicalAudience": {
                "@type": "MedicalAudience",
                "audienceType": [
                    "Consumer",
                    "Caregiver"
                ],
                "healthCondition": {
                    "@id": "https://www.rexulti.com/aad/living-with-agitation-in-alzheimers/#medcondition"
                }
            },
            "about": [
                {
                    "@type": "Drug",
                    "@id": "https://www.rexulti.com/#drug"
                },
                {
                    "@type": "MedicalCondition",
                    "@id": "https://www.rexulti.com/aad/living-with-agitation-in-alzheimers/#medcondition"
                },
                {
                    "@id": "https://www.rexulti.com/aad/#indication"
                }
            ],
            "publisher": {
                "@id": "https://otsuka-us.com/#organization"
            },
            "specialty": {
                "@type": "MedicalSpecialty",
                "name": "Psychiatry"
            }
        },
        {
            "@type": "TreatmentIndication",
            "@id": "https://www.rexulti.com/aad/#indication",
            "name": "Agitation that may happen with dementia due to Alzheimer’s disease",
            "description": "REXULTI is a prescription medicine used to treat agitation that may happen with dementia due to Alzheimer’s disease. REXULTI should not be used as an “as needed” treatment for agitation that may happen with dementia due to Alzheimer’s disease.",
            "url": "https://www.agitationinalz.com/",
            "sameAs": [
                "https://www.wikidata.org/wiki/Q4692699",
                "https://en.wikipedia.org/wiki/Agitation_(dementia)"
            ],
            "code": {
                "@type": "MedicalCode",
                "codeValue": "F03.911",
                "codingSystem": "ICD-10"
            },
            "relevantSpecialty": "https://schema.org/Psychiatric",
            "recognizingAuthority": {
                "@type": "Organization",
                "name": "U.S. Food and Drug Administration (FDA)",
                "url": "https://www.fda.gov"
            }
        },
        {
            "@type": "SiteNavigationElement",
            "@id": "https://www.rexulti.com/aad/#header-navigation",
            "name": "REXULTI AADAD Website Main Navigation",
            "url": "https://www.rexulti.com/aad",
            "isPartOf": {
                "@id": "https://www.rexulti.com/aad/#medwebpage"
            },
            "hasPart": [
                {
                    "@type": "MedicalWebPage",
                    "@id": "https://www.rexulti.com/aad/why-rexulti/#medwebpage",
                    "name": "Why Rexulti",
                    "url": "https://www.rexulti.com/aad/why-rexulti"
                },
                {
                    "@type": "MedicalWebPage",
                    "@id": "https://www.rexulti.com/aad/living-with-agitation-in-alzheimers/#medwebpage",
                    "name": "About this Condition",
                    "url": "https://www.rexulti.com/aad/living-with-agitation-in-alzheimers"
                },
                {
                    "@type": "MedicalWebPage",
                    "@id": "https://www.rexulti.com/aad/symptom-questionnaire/#medwebpage",
                    "name": "Symptom Questionnaire",
                    "url": "https://www.rexulti.com/aad/symptom-questionnaire"
                },
                {
                    "@type": "MedicalWebPage",
                    "@id": "https://www.rexulti.com/aad/disease-impact/#medwebpage",
                    "name": "Disease Impact",
                    "url": "https://www.rexulti.com/aad/disease-impact"
                },
                {
                    "@type": "MedicalWebPage",
                    "@id": "https://www.rexulti.com/aad/doctor-discussion-guide/#medwebpage",
                    "name": "Talk to your loved one's doctor",
                    "url": "https://www.rexulti.com/aad/doctor-discussion-guide"
                },
                {
                    "@type": "MedicalWebPage",
                    "@id": "https://www.rexulti.com/aad/resources-and-organizations/#medwebpage",
                    "name": "Resources and Organizations",
                    "url": "https://www.rexulti.com/aad/resources-and-organizations"
                },
                {
                    "@type": "MedicalWebPage",
                    "@id": "https://www.rexulti.com/aad/frequently-asked-questions/#faqpage",
                    "name": "Questions and Answers",
                    "url": "https://www.rexulti.com/aad/frequently-asked-questions"
                },
                {
                    "@type": "MedicalWebPage",
                    "@id": "https://www.rexulti.com/aad/helpful-videos/#medwebpage",
                    "name": "Helpful Videos",
                    "url": "https://www.rexulti.com/aad/helpful-videos"
                },
                {
                    "@type": "MedicalWebPage",
                    "@id": "https://www.rexulti.com/aad/caregiver-registration/#medwebpage",
                    "name": "Share your caregiver story",
                    "url": "https://www.rexulti.com/aad/caregiver-registration"
                }
            ]
        },
        {
            "@type": "BreadcrumbList",
            "@id": "https://www.rexulti.com/aad/#breadcrumb",
            "itemListElement": [
                {
                    "@type": "ListItem",
                    "position": 1,
                    "name": "Home",
                    "item": "https://www.rexulti.com/"
                },
                {
                    "@type": "ListItem",
                    "position": 2,
                    "name": "AAD",
                    "item": "https://www.rexulti.com/aad/"
                }
            ]
        },
        {
            "@type": "Organization",
            "@id": "https://otsuka-us.com/#organization",
            "name": "Otsuka America Pharmaceutical, Inc.",
            "url": "https://otsuka-us.com/",
            "logo": {
                "@type": "ImageObject",
                "@id": "https://otsuka-us.com/#logo",
                "url": "https://www.otsuka-us.com/sites/g/files/qhldwo12546/themes/site/themes/custom/otsuka_corp/logo.svg",
                "width": 75,
                "height": 31,
                "caption": "Ostuka logo"
            },
            "brand": {
                "@id": "https://www.rexulti.com/#brand"
            },
            "sameAs": [
                "https://www.facebook.com/OtsukaUS",
                "https://twitter.com/otsukaus",
                "https://www.instagram.com/otsuka_us/",
                "https://www.threads.net/@otsuka_us",
                "https://www.youtube.com/@otsukaus416"
            ]
        },
        {
            "@type": "Brand",
            "@id": "https://www.rexulti.com/#brand",
            "name": "REXULTI®",
            "url": "https://www.rexulti.com/",
            "logo": {
                "@type": "ImageObject",
                "@id": "https://www.rexulti.com/#logo",
                "url": "https://www.rexulti.com/sites/g/files/qhldwo12851/files/logo%403x.png",
                "width": 600,
                "height": 261,
                "caption": "Rexulti logo"
            },
            "description": "REXULTI is a prescription medicine used: along with antidepressant medicines to treat major depressive disorder (MDD) in adults; to treat agitation that may happen with dementia due to Alzheimer’s disease"
        }
    ]
}

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: REXULTI (Otsuka America Pharmaceutical, Inc.) (rexulti.com)

https://rexulti.com 📍 Industry: Medical Devices, Pharma & Biotech
11 BS / 100

A rare example of a low-BS website where regulatory constraints actually force high substance. The site provides specific pricing, clinical risks, and clear therapeutic boundaries without hiding behind marketing obfuscation.

Info Density Power-words vs. Substance ratio.
3
10% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
1
5% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
2
10% BS
Commodity Fingerprint Detection of industry clichés/templates.
4
27% BS
Identity & Authority Expert verifiability & Schema depth.
1
7% BS

To achieve a near-zero score, explicitly clarify the source of the review_count in the schema to ensure it isn’t mistaken for consumer ratings. Add direct DOI or PubMed links to the peer-reviewed clinical trial data mentioned in the prescribing info directly onto the condition pages. Ensure the IQVIA data is updated as it approaches the 12-month stale mark from the current 2026 anchor. Replace the metaphorical ‘BOOST’ language in MDD headings with clinical terminology to maintain total technical consistency.

The site aligns perfectly with the Pharma and Biotech category, characterized by heavy regulatory compliance, structured safety information, and clear indications for use. The content is dominated by pharmacovigilance requirements and clinical descriptors like adjunctive therapy and atypical antipsychotics.

“The score of 11 is driven by the necessary but formulaic commodity fingerprint of pharma websites and minor marketing repetition. The site excels in Information Density and Semantic Coherence, providing high-value technical and financial data that backs up every claim.”

Verified Analysis Date: June 19, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution

This training module utilizes a snapshot of public data from REXULTI (Otsuka America Pharmaceutical, Inc.), captured on June 19, 2026, to demonstrate how machine logic evaluates different types of business narratives.

Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.

Notice to REXULTI (Otsuka America Pharmaceutical, Inc.): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.

Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.

To all users: You are encouraged to visit the live site at https://rexulti.com to view the most current version of its content and learn from the source what this company is about and what it offers.